Peripheral blood CD34+ peak during mobilisation as an additional parameter to assess PBSC inoculum adequacy autologous HSCT
5 affiliations
- 1Istituto Oncologico del Mediterraneo, Hematopoietic Stem Cell Transplantation (HSCT) Unit-Viagrande
- 2Programma di Trapianto Emopoietico - Hematopoietic Stem Cell Transplantation (HSCT) Unit-Policlinico di Catania
- 3Department of Experimental Medicine (DIMES), University of Genoa
- 4Istituto Nazionale Fisica Nucleare
- 5Institute of Particle and Nuclear Physics, Charles University
Abstract
Background: After autologous haematopoietic stem cell transplantation (HSCT), the infused CD34+ cell dose is usually considered essential for assessing the adequacy of the peripheral blood progenitor cells (PBSC) inoculum.
Methods: In a cohort of 302 patients who underwent autologous haematopoietic transplantation, we investigated whether the peak peripheral blood CD34+ cell count during mobilisation could predict neutrophil engraftment.
Results: In the overall cohort, the mean time to neutrophil engraftment was 12.2 days, and the mean infused CD34+ cell dose was 5.1 × 10^6 CD34+ cells/kg. In univariate analysis, the CD34+ cell dose (p=0.005), the PB CD34+ peak during mobilisation (p=0.0002), the number of performed apheresis (p=0.03), and the use of G-CSF (p=0.001) were significantly associated with time to neutrophil engraftment. When factors were evaluated in multivariate analysis, the PB CD34+ peak and use of G-CSF remained significant. In a ROC analysis, the PB CD34+ peak predicted delayed engraftment with an AUC of 0.695 (95% CI, 0.599-0.791). Joint stratification by PB CD34+ peak and infused CD34+ dose identified subgroups at high risk of delayed engraftment.
Conclusion: In patients treated by autologous HSCT and receiving an adequate dose of infused CD34+ cells, the PB CD34+ peak during mobilisation is independently associated with post-transplant neutrophil engraftment.
Related
- Human iPSCs and iPSC-Derived Endothelial Cells from PAD Patients and Healthy Donors Exhibit Comparable Characteristics and Potency: Implications for Autologous Cell Therapy in Peripheral Artery Disease
- Type 1 diabetes impairs the mobilisation of highly-differentiated CD8+ T cells during a single bout of acute exercise
- Inoculum-dependent activity of contemporary β-lactam agents against carbapenemase- producing Enterobacterales
- Plant genetic and root‐associated microbial diversity modulate Lactuca sativa responsiveness to a soil inoculum under phosphate deficiency
- Inoculum-to-interface distance tunes productivity in static liquid cultures of wood-decay fungi
BibTeX
@article{milone2026peripheral,
title = {{Peripheral blood CD34+ peak during mobilisation as an additional parameter to assess PBSC inoculum adequacy autologous HSCT}},
author = {Giuseppe Milone and Emanuele Martorana and Maria Grazia Camuglia and Salvatore Leotta and Andrea Spadaro and Giulia Giuffrida and Gaetano Moschetti and Federica Galbo and Paola Scirè and Giulio Antonio Milone and Giordana Brunetti and Paolo Castorina},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1935217},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1935217/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Peripheral blood CD34+ peak during mobilisation as an additional parameter to assess PBSC inoculum adequacy autologous HSCT
AU - Giuseppe Milone
AU - Emanuele Martorana
AU - Maria Grazia Camuglia
AU - Salvatore Leotta
AU - Andrea Spadaro
AU - Giulia Giuffrida
AU - Gaetano Moschetti
AU - Federica Galbo
AU - Paola Scirè
AU - Giulio Antonio Milone
AU - Giordana Brunetti
AU - Paolo Castorina
PY - 2026
DA - 2026/10/16
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1935217
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1935217/full
AB - Background: After autologous haematopoietic stem cell transplantation (HSCT), the infused CD34+ cell dose is usually considered essential for assessing the adequacy of the peripheral blood progenitor cells (PBSC) inoculum. Methods: In a cohort of 302 patients who underwent autologous haematopoietic transplantation, we investigated whether the peak peripheral blood CD34+ cell count during mobilisation could predict neutrophil engraftment. Results: In the overall cohort, the mean time to neutrophil engraftment was 12.2 days, and the mean infused CD34+ cell dose was 5.1 × 10^6 CD34+ cells/kg. In univariate analysis, the CD34+ cell dose (p=0.005), the PB CD34+ peak during mobilisation (p=0.0002), the number of performed apheresis (p=0.03), and the use of G-CSF (p=0.001) were significantly associated with time to neutrophil engraftment. When factors were evaluated in multivariate analysis, the PB CD34+ peak and use of G-CSF remained significant. In a ROC analysis, the PB CD34+ peak predicted delayed engraftment with an AUC of 0.695 (95% CI, 0.599-0.791). Joint stratification by PB CD34+ peak and infused CD34+ dose identified subgroups at high risk of delayed engraftment. Conclusion: In patients treated by autologous HSCT and receiving an adequate dose of infused CD34+ cells, the PB CD34+ peak during mobilisation is independently associated with post-transplant neutrophil engraftment.
SN - 1664-3224
ER -